CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma-Reference-Cited by-同舟云学术

CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma

Published:2013-08-15 Issue:7 Volume:122 Page:1233-1242
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Bhatt Shruti¹²,Ashlock Brittany M.³,Natkunam Yasodha⁴,Sujoy Victoria⁵,Chapman Jennifer Rose⁵,Ramos Juan Carlos²,Mesri Enrique A.³,Lossos Izidore S.¹²

Affiliation:

1. Department of Molecular and Cellular Pharmacology,

2. Department of Medicine, Division of Hematology-Oncology, and

3. Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL;

4. Department of Pathology, Stanford University School of Medicine, Stanford, CA; and

5. Department of Pathology, University of Miami Miller School of Medicine, Miami, FL

Abstract

Key Points Brentuximab vedotin serves as an effective therapy for PEL. Brentuximab vedotin led to cytotoxic effects in PEL cell lines and extended survival of xenograft mice.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/7/1233/1374010/1233.pdf

Reference32 articles.

1. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.;Cesarman;N Engl J Med,1995

2. Primary-effusion lymphoma and Kaposi’s sarcoma in a cardiac-transplant recipient.;Jones;N Engl J Med,1998

3. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus.;Nador;Blood,1996

4. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.;Arvanitakis;Blood,1996

5. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma.;Chang;Science,1994

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Promising immunotherapeutic approaches for primary effusion lymphoma;Exploration of Targeted Anti-tumor Therapy;2024-06-26

2. Clinicopathologic features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma;American Journal of Clinical Pathology;2024-02-22

3. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

4. Monoclonal Antibodies in Oncology: A Decade of Novel Options;Cell Biochemistry and Biophysics;2023-07-03

5. CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model;FEBS Open Bio;2023-05-15